Stockscreener 앱 받기
10.22
2.29%
-0.24
전일 마감가:
$10.46
열려 있는:
$10.48
하루 거래량:
1.47M
Relative Volume:
0.79
시가총액:
$889.32M
수익:
-
순이익/손실:
$-168.09M
주가수익비율:
-4.7097
EPS:
-2.17
순현금흐름:
$-138.01M
1주 성능:
-14.48%
1개월 성능:
-4.31%
6개월 성능:
+53.45%
1년 성능:
+5.47%
1일 변동 폭
$10.17
$10.56
1주일 범위
$10.17
$12.31
52주 변동 폭
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
명칭
Kura Oncology Inc
전화
(858) 500-8800
주소
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
KURA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
10.22 | 910.20M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-04 | 개시 | Guggenheim | Neutral |
| 2025-02-06 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-14 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-08-11 | 개시 | BofA Securities | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Perform |
| 2023-05-17 | 개시 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2022-07-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-15 | 개시 | Jefferies | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-11-05 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-11-09 | 개시 | Piper Jaffray | Overweight |
| 2018-08-01 | 개시 | H.C. Wainwright | Buy |
| 2016-10-13 | 재개 | Leerink Partners | Outperform |
| 2016-01-22 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-30 | 개시 | Oppenheimer | Outperform |
| 2015-12-16 | 개시 | Citigroup | Buy |
모두보기
Kura Oncology Inc 주식(KURA)의 최신 뉴스
EcoR1 Capital LLC Boosts Stock Position in Kura Oncology, Inc. $KURA - MarketBeat
(KURA) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Kura Oncology, Inc. $KURA Shares Sold by Armistice Capital LLC - MarketBeat
Kura Oncology, Kyowa Kirin reveal Komsifti combo data for AML - MSN
Insider Sell: Faheem Hasnain Sells 10,000 Shares of Kura Oncology Inc (KURA) - GuruFocus
Insiders Find Solace Selling US$1.4m In Stock With Kura Oncology's Price Down 11% - 富途牛牛
Kura Oncology stock maintains Market Outperform rating at Citizens By Investing.com - Investing.com Canada
Kura Oncology, Inc. (KURA) Fundamental Analysis - Meyka
Kura Oncology (KURA) Reports Promising AML Trial Results - GuruFocus
Kura Oncology, Kyowa Kirin Report 'Encouraging' Drug Combo Data to Treat Acute Myeloid Leukemia - marketscreener.com
Kura Oncology & Kyowa Kirin announce positive Komzifti combination data for acute myeloid - marketscreener.com
Kura Oncology completes first U.S. commercial sale of KOMZIFTI - MSN
Kura Oncology (KURA) Reveals Positive Leukemia Treatment Data - GuruFocus
Kura Oncology and Kyowa Kirin Report Promising Data for KOMZIFTI in Combination Therapy for Acute Myeloid Leukemia at ASH 2025 - Quiver Quantitative
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML - The Manila Times
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML - marketscreener.com
Kura Oncology, Inc. $KURA Shares Sold by Walleye Capital LLC - MarketBeat
What analysts say about Kura Oncology Inc stockStock Buy Signals & Free Real-Time Trading Alerts Every Day - earlytimes.in
Price Clustering Detected in Bhaskar Agrochemicals Limited StockVolatility Index Analysis & Reap the Rewards of Patience + Planning - earlytimes.in
Why The Narrative Around Kura Oncology Is Shifting After Komzifti’s FDA Breakthrough - Yahoo Finance
Kura Oncology stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Franklin Resources Inc. Decreases Stake in Kura Oncology, Inc. $KURA - MarketBeat
FDA approved five NMEs in November - biocentury.com
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - The Malaysian Reserve
Kura Oncology (NASDAQ:KURA) Trading Up 7.3%What's Next? - MarketBeat
Kura Oncology: A Cautious Buy (NASDAQ:KURA) - Seeking Alpha
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia - The Manila Times
Kura Oncology completes first commercial sale of leukemia drug By Investing.com - Investing.com Canada
Geode Capital Management LLC Purchases 211,470 Shares of Kura Oncology, Inc. $KURA - MarketBeat
Kura Oncology (NASDAQ: KURA) plans Dec. 8 webcast on ASH 2025 AML triplet study data - Stock Titan
Kura Oncology Announces First U.S. Sale of KOMZIFTI - MSN
Kura Oncology (KURA) Is Down 7.2% After First KOMZIFTI Sale Triggers $135M Milestone Payment - simplywall.st
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data (NASDAQ:KURA) - Seeking Alpha
Kura Oncology, Inc. Completes Collaboration and License Agreement with Kyowa Kirin - marketscreener.com
Kura Oncology Expects $135 Million Milestone Payment for First US Sale of Komzifti - marketscreener.com
Kura Oncology announces first US sale of KOMZIFTI, triggering $135 million payment - Investing.com Nigeria
Kura Oncology (KURA) Secures $135 Million Milestone with KOMZIFT - GuruFocus
Kura Oncology announces first US sale of KOMZIFTI, triggering $135 million payment By Investing.com - Investing.com South Africa
Kura Oncology completes first commercial sale of leukemia drug - Investing.com
First U.S. commercial sale of Komzift triggers $135 million milestone payment to Kura Oncology - marketscreener.com
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin - The Manila Times
Kura Oncology (Nasdaq: KURA) to receive $135M as KOMZIFTI launches in U.S. market - Stock Titan
How Kura Oncology Inc. stock trades during market volatilityRate Hike & Daily Growth Stock Investment Tips - Newser
How geopolitical tensions affect Kura Oncology Inc. stockWeekly Stock Report & Technical Confirmation Trade Alerts - Newser
How rising interest rates impact Kura Oncology Inc. stock - Newser
Is Megatherm Induction Limited Stock a Strong Buy According to Wall StreetLarge Cap Stability Picks & Free Unlock Stock Analysis - earlytimes.in
Rhenman & Partners Asset Management AB Boosts Stake in Kura Oncology, Inc. $KURA - MarketBeat
Magnetar Financial LLC Buys 64,345 Shares of Kura Oncology, Inc. $KURA - MarketBeat
Foresite Capital Management IV LLC Has $4.71 Million Holdings in Kura Oncology, Inc. $KURA - MarketBeat
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML) - The Manila Times
Kura Oncology’s leukemia drug added to NCCN treatment guidelines By Investing.com - Investing.com Australia
Kura Oncology Inc (KURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):